drugset / Trial / NCT00426998

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998

Phase 2 Completed 30 enrolled Retinal Consultants Medical Group
RandomizedFactorialOpen-labelTreatment

Summary

The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).

Timeline

Start
2006-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody
Subject Verteporfin Other / unclassified